Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer
June 01, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
- Dr. Russell to report to Dr. Erin Quirk, President and Head of Research & Development FOSTER CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the...
Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates
May 16, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
-IND opened for NASH Phase 2a trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist); trial initiated with top-line data expected in second half of 2023 -TERN-601...
Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
April 04, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201
March 21, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
March 03, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
-Top-line data readout from TERN-201 (VAP-1 inhibitor) clinical trial in NASH expected in March 2022 -Initiation of Terns’ first NASH trial of TERN-501 (THR-β agonist) alone and in combination with...
Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference
February 28, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer
January 06, 2022 07:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference
January 03, 2022 16:05 ET
|
Terns Pharmaceuticals, Inc.
FOSTER CITY, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of...
Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
November 15, 2021 16:05 ET
|
Terns Pharmaceuticals, Inc.
-Top-line data readout from TERN-201 (VAP-1) clinical trial in NASH expected in 1Q 2022 -Positive top-line data from TERN-501 (THR-β) demonstrated clinical proof of concept, enabling the planned...
Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021
November 12, 2021 07:05 ET
|
Terns Pharmaceuticals, Inc.
Oral presentation of data from Phase 2a LIFT Trial of TERN-101, demonstrating differentiated safety and efficacy profiles 12 weeks of TERN-101 treatment significantly decreases cT1, a marker of...